samedan logo
 
 
 
spacer
home > ebr > spring 2003 > capital markets slowdown triggers pharma micro-deals in 2002
PUBLICATIONS
European Biopharmaceutical Review

Capital Markets Slowdown Triggers Pharma Micro-Deals in 2002

In 2002 the ability of companies to raise funds on either the public or private markets was greatly restricted, triggering a substantial reduction in the average value of M&A deals in the pharma sector.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Neal Ransome, Partner at PricewaterhouseCoopers

Neal Ransome is the European leader of PricewaterhouseCoopers' Pharmaceuticals and Healthcare Corporate Finance team. He has over 10 years' experience of corporate finance transactions, and has been focusing on the pharma and health care sectors since 1997. Neal's clients in the sector have included large pharma companies such as GlaxoSmithKline and Aventis, emerging companies such as Powderject and a wide range of smaller clients in the health care and biotech sectors.

Neal has also acted for a large number of private equity clients in the sector, including 3i, Warburg Pincus and Phoenix. The European team which he leads comprises approximately 20 professional staff, located in all key financial centres, and combines corporate finance experts with recruits from the industry.

spacer
Neal Ransome
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement